| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJI.12460 |
| P698 | PubMed publication ID | 26685057 |
| P50 | author | Annemarie Hennessy | Q37837597 |
| Åsa Nääv | Q59158349 | ||
| P2093 | author name string | Daniel Vaiman | |
| Stefan R Hansson | |||
| Bo Åkerström | |||
| Magnus Gram | |||
| Lena Erlandsson | |||
| P2860 | cites work | Nitroso-redox balance and mitochondrial homeostasis are regulated by STOX1, a pre-eclampsia-associated gene | Q24294779 |
| Up-regulation of A1M/α1-microglobulin in skin by heme and reactive oxygen species gives protection from oxidative damage | Q28477940 | ||
| Abnormal development of placenta in HtrA1-deficient mice | Q28504581 | ||
| The vascular effects of sodium tanshinone IIA sulphonate in rodent and human pregnancy | Q28545010 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes | Q33312878 | ||
| STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas | Q33392665 | ||
| Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation | Q33490821 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model | Q34173305 | ||
| Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice | Q34517776 | ||
| Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment | Q34565651 | ||
| The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature | Q35002391 | ||
| 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model | Q35151065 | ||
| A current concept of eclampsia | Q35156657 | ||
| Exposure to experimental preeclampsia in mice enhances the vascular response to future injury | Q35175524 | ||
| Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes | Q35294235 | ||
| A1M Ameliorates Preeclampsia-Like Symptoms in Placenta and Kidney Induced by Cell-Free Fetal Hemoglobin in Rabbit | Q35586953 | ||
| The Dahl salt-sensitive rat is a spontaneous model of superimposed preeclampsia | Q35817935 | ||
| Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency | Q35864583 | ||
| A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model | Q36115311 | ||
| Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. | Q36357886 | ||
| The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy | Q36407259 | ||
| Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-α. | Q36528002 | ||
| Animal models of human placentation--a review | Q36695431 | ||
| A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice | Q36752126 | ||
| The role of the immune system in preeclampsia | Q36791219 | ||
| The glomerular injury of preeclampsia | Q36883342 | ||
| The two stage model of preeclampsia: variations on the theme | Q37187589 | ||
| Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model | Q37311066 | ||
| Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia | Q37451538 | ||
| A1M/α1-microglobulin protects from heme-induced placental and renal damage in a pregnant sheep model of preeclampsia | Q37525221 | ||
| Evolution of invasive placentation with special reference to non-human primates | Q37807636 | ||
| Animal models of pre-eclampsia. | Q37816496 | ||
| Animal models of preeclampsia; uses and limitations | Q37865890 | ||
| Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin | Q37983081 | ||
| Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy | Q38159353 | ||
| A1M, an extravascular tissue cleaning and housekeeping protein | Q38230811 | ||
| Carbohydrate groups of alpha1-microglobulin are important for secretion and tissue localization but not for immunological properties | Q38308339 | ||
| Resveratrol inhibits trophoblast apoptosis through oxidative stress in preeclampsia-model rats. | Q38929137 | ||
| Bystander cell death and stress response is inhibited by the radical scavenger α(1)-microglobulin in irradiated cell cultures | Q39642906 | ||
| The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species | Q39949399 | ||
| Inhibition of activin A signalling in a mouse model of pre-eclampsia | Q40772947 | ||
| Only humans have human placentas: molecular differences between mice and humans | Q41147917 | ||
| Distribution of iodine 125-labeled alpha1-microglobulin in rats after intravenous injection. | Q42500896 | ||
| Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats | Q43207984 | ||
| A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia | Q43258263 | ||
| Pregnancy-induced hypertension: development of a model in the pregnant sheep | Q43410452 | ||
| Production of protein HC by human fetal liver explants | Q44019427 | ||
| Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. | Q44044678 | ||
| TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas | Q45102738 | ||
| Interleukin-10 regulates arterial pressure in early primate pregnancy | Q45225611 | ||
| Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats | Q46298778 | ||
| Decreased mitochondrial fatty acid oxidation in placentas from women with preeclampsia | Q46325532 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Discovery of a spontaneous genetic mouse model of preeclampsia | Q46351794 | ||
| Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. | Q46357680 | ||
| Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family | Q46418228 | ||
| Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia | Q46542318 | ||
| Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia | Q46765356 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Endothelial dysfunction in preeclampsia | Q47879591 | ||
| Low-dose nitro-L-arginine administration in baboon (Papio hamadryas) pregnancy. | Q51433437 | ||
| The pathogenetic role of heme in pregnancy-induced hypertension-like disease in ewes. | Q51571837 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Effect of Sildenafil on Pre-Eclampsia-Like Mouse Model Induced By L-Name. | Q53512573 | ||
| Tumor necrosis factor α induces a model of preeclampsia in pregnant baboons (Papio hamadryas). | Q54360788 | ||
| Pregnancy-induced hypertension: development of a model in the pregnant primate (Papio anubis). | Q54452496 | ||
| Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. | Q54570213 | ||
| P433 | issue | 3 | |
| P921 | main subject | pre-eclampsia | Q61335 |
| maternal health | Q6786626 | ||
| P304 | page(s) | 402-410 | |
| P577 | publication date | 2015-12-18 | |
| P1433 | published in | American Journal of Reproductive Immunology | Q15761228 |
| P1476 | title | Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities | |
| P478 | volume | 75 |
| Q57029323 | Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice |
| Q64236205 | High glutathionylation of placental endothelial nitric oxide synthase in preeclampsia |
| Q92647905 | Long-term cardiovascular disorders in the STOX1 mouse model of preeclampsia |
| Q39283914 | New Models of Pregnancy-Associated Hypertension |
| Q42373442 | Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function |
| Q36141421 | Postpartum Vascular Dysfunction in the Reduced Uteroplacental Perfusion Model of Preeclampsia |
| Q33917113 | Treating the dysfunctional placenta |
| Q52742769 | [New perspectives on preeclampsia]. |
Search more.